TY - JOUR
T1 - Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing
AU - Varley, Katherine E.
AU - Mutch, David G.
AU - Edmonston, Tina B.
AU - Goodfellow, Paul J.
AU - Mitra, Robi D.
N1 - Funding Information:
Siteman Cancer Center Endometrial Cancer Working Group Research Development Award; Genome Analysis Training Program [T32 HG000045]; Center for Excellence in Genome Sciences grant from National Human Genome Research Institute [5P50HG003170-03]; Epigenetics Roadmap grant [1R01DA025744-01]. Funding for open access charge: National Institutes of Health grant# 1R01DA025744.
PY - 2009
Y1 - 2009
N2 - A single tumor may contain cells with different somatic mutations. By characterizing this genetic heterogeneity within tumors, advances have been made in the prognosis, treatment and understanding of tumorigenesis. In contrast, the extent of epigenetic intra-tumor heterogeneity and how it influences tumor biology is under-explored. We have characterized epigenetic heterogeneity within individual tumors using next-generation sequencing. We used deep single molecule bisulfite sequencing and sample-specific DNA barcodes to determine the spectrum of MLH1 promoter methylation across an average of 1000 molecules in each of 33 individual samples in parallel, including endometrial cancer, matched blood and normal endometrium. This first glimpse, deep into each tumor, revealed unexpectedly heterogeneous patterns of methylation at the MLH1 promoter within a subset of endometrial tumors. This high-resolution analysis allowed us to measure the clonality of methylation in individual tumors and gain insight into the accumulation of aberrant promoter methylation on both alleles during tumorigenesis.
AB - A single tumor may contain cells with different somatic mutations. By characterizing this genetic heterogeneity within tumors, advances have been made in the prognosis, treatment and understanding of tumorigenesis. In contrast, the extent of epigenetic intra-tumor heterogeneity and how it influences tumor biology is under-explored. We have characterized epigenetic heterogeneity within individual tumors using next-generation sequencing. We used deep single molecule bisulfite sequencing and sample-specific DNA barcodes to determine the spectrum of MLH1 promoter methylation across an average of 1000 molecules in each of 33 individual samples in parallel, including endometrial cancer, matched blood and normal endometrium. This first glimpse, deep into each tumor, revealed unexpectedly heterogeneous patterns of methylation at the MLH1 promoter within a subset of endometrial tumors. This high-resolution analysis allowed us to measure the clonality of methylation in individual tumors and gain insight into the accumulation of aberrant promoter methylation on both alleles during tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=69049103181&partnerID=8YFLogxK
U2 - 10.1093/nar/gkp457
DO - 10.1093/nar/gkp457
M3 - Article
C2 - 19494183
AN - SCOPUS:69049103181
SN - 0305-1048
VL - 37
SP - 4603
EP - 4612
JO - Nucleic acids research
JF - Nucleic acids research
IS - 14
ER -